Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Validating ctDNA-based approaches in clinical trials

Marla Lipsyc-Sharf • 4 Jun 2022
ASCO 2022
General

Marla Lipsyc-Sharf, MD, Dana-Farber Cancer Institute, Boston, MA, talks on key challenges associated with the implementation of circulating tumor DNA (ctDNA) and liquid biopsy approaches in clinical practice. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Marla Lipsyc-Sharf

ctDNA vs. pathological markers
0:25
ctDNA vs. pathological markers
Marla Lipsyc-Sharf • 4 Jun 2022
ctDNA and late recurrence in high-risk, HR+, HER2- breast cancer
1:46
ctDNA and late recurrence in high-risk, HR+, HER2- breast cancer
Marla Lipsyc-Sharf • 4 Jun 2022

Related Videos

AI governance and validation in robotic cancer surgery
1:12
AI governance and validation in robotic cancer surgery
Marie Hanaoka • 1 Jul 2026
Does toxicity differ between patients treated with SABR for one versus five lesions?
0:39
Does toxicity differ between patients treated with SABR for one versus five lesions?
Robert Olson • 16 May 2026
5-year toxicity following SABR: insights from the SABR-5 trial
0:42
5-year toxicity following SABR: insights from the SABR-5 trial
Robert Olson • 16 May 2026
How should results from the SABR-5 trial guide future SABR studies?
1:05
How should results from the SABR-5 trial guide future SABR studies?
Robert Olson • 16 May 2026
The content of VJOncology is intended for healthcare professionals